ALK-Abelló has teamed up with the Copenhagen University Hospital (Rigshospitalet) and NOVI Innovation A/S to start up a new company, T-Shift, to explore innovative new research fields within allergy treatment with a view to developing increasingly more effective and user-friendly vaccines. The company builds on a patent-pending technology which makes it possible to intervene in the immune system. ALK-Abelló has prior-use rights to the technology in the allergy field.